Monoclonal Antibodies in Asthma Therapy. Yehia El-Gamal MD, PhD
|
|
- Magdalene French
- 8 years ago
- Views:
Transcription
1 Monoclonal Antibodies in Asthma Therapy Yehia El-Gamal MD, PhD
2 Conflict of Interest Nothing to disclose
3 Objectives Following this presentation, the audience should be able to: Recognize some important monoclonal antibodies available for asthma therapy. Identify candidates for treatment with monoclonal antibodies. Be aware of the side effects and cost- benefit of such therapy.
4 Since the first publication by Kohler and Milstein on the production of murine monoclonal antibodies (MAbs) by hybridoma technology, therapeutic use of MAbs has become a major part of treatments in various diseases. Köhler G, Milstein C. Nature 1975;256: oclonal_antibodies
5 Schematic representation of MAb production Martin-Mateos Mateos MA. Allergol Immunopathol (Madr) 2007; 35(4):
6 MAbs in allergic diseases (cont d) Omalizumab (anti-ige ab) It is a recombinant humanized monoclonal antibody (rhumab-e25) developed by immunizing mice with human IgE. Then, a monoclonal antibody was selected that recognizes IgE at the same site as the high-affinity receptor for IgE (FcεRI). Milgrom H, et al. N Engl J Med 1999;341(26):
7 MAbs in allergic diseases (cont d) Omalizumab is the only MAb to date that has been found to be effective and approved by both the FDA and European Medicines Agency (EMEA) for the treatment of difficult allergic asthma. Bousquet J, et al. Expert Opin Biol Ther 2008;8(12):
8 Mechanisms of Action of Omalizumab Reduces serum levels of free IgE Down-regulates expression of IgE receptors (FceRI) on mast cells and basophils. In the airways of patients with allergic asthma, it reduces FcεRI+ and IgE+ cells and causes a profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell T and B-cell B numbers. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. J Allergy Clin Immunol 2005;115(3):
9 Mechanisms of action of omalizumab (cont d) The reductions in circulating levels of IgE resulting from omalizumab treatment leads to reductions in FceRI expression on mast cells, basophils and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia, levels of GM-CSF, IL-2, IL-4, IL-5 5 and IL-13. It may also reduce allergen presentation to T-T cells and the production of Th2 cytokines. Holgate S, et al. Allergy 2009:64(12):
10 Fig 2 Proposed Mechanisms of Action of Omalizumab Holgate S, et al. J Allergy Clin Immunol 2005;115(3): Source: Journal of Allergy and ClinOI: /j.jaci )
11 Treatment of allergic asthma with monoclonal anti-ige antibody: rhumab-e25 Study Group. Serum concentrations of total and free IgE in subjects given a low dose of rhumab-e25 for 20 weeks Milgrom H, et al. N Engl J Med Dec 23;341(26):
12 Immunohistochemical staining of bronchial biopsy specimens before (left( left) ) and after (right( right) ) 16 weeks of omalizumab treatment. Representative sections show staining with antibody against: ECP (A and B) Cell-surface IgE (C and D) High-affinity IgE R (E and F) IL-4 (G and H) Djukanović R, et al. Am J Respir Crit Care Med 2004;170: Fig 1
13 Eosinophil apoptosis at baseline and week 12 of omalizumab therapy: The omalizumab group (n = 9) demonstrated a significant increase in Annexin-positive eosinophils compared with placebo (n = 10). p < 0.01 Fig 1 Noga O,et al. J Allergy Clin Immunol 2006;117:
14 Individual eosinophil counts at baseline and after 12 weeks of treatment with omalizumab or placebo. Horizontal bars represent median values van Rensen E, et al. Allergy 2009;64:72 80.
15 Forced expiratory volume in 1 second as a percentage of baseline in the placebo (A) and omalizumab (B) groups. van Rensen E, et al. Allergy 2009;64:72 80.
16 Effect of add-on therapy with omalizumab in patients with severe persistent asthma whose asthma was inadequately controlled by therapy with high-dose ICSs plus a LABA Humbert M, et al. Allergy 2005; 60:309 16
17 Anti-IgE Therapy in Children Omalizumab is approved for the treatment of adults and adolescents (12 years) with inadequately controlled moderate-to to-severe (United States) or severe (Europe) allergic (IgE- mediated) asthma. m. A randomized DBPC study in 334 children (6 to 12 years) with moderate-to to-severe allergic asthma, omalizumab significantly reduced asthma exacerbations and enabled reductions in ICS dose. Milgrom H, et al. Pediatrics 2001;108:E36.
18 Anti-IgE Therapy in Children (cont d) More recently, Lanier et al. demonstrated, in a RDBPC trial, that add-on therapy with omalizumab has a reassuring safety profile, with no increased risk of adverse events, and reduces asthma exacerbations in children (66 to <12 years) with inadequately controlled moderate-to to- severe allergic asthma. Lanier B, et al. J Allergy Clin Immunol 2009;124:
19 Fig 2 Clinically significant asthma exacerbation rates over a period of 24 weeks (primary outcome; A) and 52 weeks (B) in patients with moderate-to to- severe asthma treated with add-on omalizumab Lanier B, et al. J Allergy Clin Immunol 2009;124(6):
20 Asthma symptom re-emergence emergence after omalizumab withdrawal The reason for omalizumab being ineffective in some patients is unknown, but it is reasonable to ask whether the failures failures result from ineffective reductions in IgE levels. Questions are being asked about whether the dose can be reduced after months of treatment or whether off-table regimens can be used. Reducing omalizumab doses may result in increase in free IgE causing deterioration in asthma control. Salvin RG, et al. J Allergy Clin Immunol 2009;123(1): MacGlashan D. J Allergy Clin Immunol 2009;123(1):114-5.
21 Omalizumab Safety Omalizumab is considered generally safe. The most common adverse reaction from omalizumab is injection- site pain and bruising but the package insert contains warnings regarding malignancies, geohelminth infections and a "black box" warning about anaphylaxis. Cox LS, et al. Allergy Asthma Clin Immunol 2009;5(1):4.
22 Omalizumab in allergic patients at risk of geohelminth infection A RDBPC trial from Brazil, conducted in 137 subjects (12 30 years), revealed that 50% of the omalizumab group experienced at least one intestinal geohelminth infection compared with 41% of the placebo subjects. This provides some evidence for a potential increased risk of geohelminth infection in subjects receiving omalizumab. Omalizumab therapy did not appear to be associated with increased morbidity attributable to intestinal helminthes or to affect response to anithelmintics. Cruz AA, et al. Clin Exp Allergy 2007; 37 :
23 Value of screening for helminth infections in patients receiving long-term omalizumab therapy The usefulness of screening for helminth infections before considering omalizumab therapy varies widely between different exposure risk groups, and is generally not necessary except in individuals with continuing exposure, a past history of filarial or schistosomal infection, and individuals with a history or high risk of infection with Strongyloides. Cooper PJ, et al. Allergy 2008;63:
24 Omalizumab and Anaphylaxis A review of post-marketing adverse events suggested that at least 0.2% of patients who received omalizumab experienced anaphylaxis between June 2003 and December Limb SL, et al. J Allergy Clin Immunol 2007;120: An Omalizumab Joint Task Force of the AAAAI and the ACAAI concluded that the anaphylaxis-reporting rate was 0.09%.It recommended an observation period of 2 hours for the first 3 injections and 30 minutes for subsequent injections as well as patient education regarding anaphylaxis. Cox L, et al. AAAAI/ACAAI Joint Task Force Report on omalizumab- associated anaphylaxis. J Allergy Clin Immunol 2007;120: Another reported incidence of anaphylaxis was 0.14% in omalizumab-treated patients and 0.07% in control patients. Corren J, et al. Clin Exp Allergy 2009;39:
25 Omalizumab and Malignancy Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab. Corren J, et al. Clin Exp Allergy 2009;39(6): No cases were considered drug-related related by a panel of blinded independent oncologists. The majority of cases (60%) were diagnosed within 6 months of treatment Cox LS, et al. Allergy Asthma Clin Immunol 2009;5(1):4. A multicenter, prospective, observational cohort study designed to evaluate the long term safety of Xolair (omalizumab) is currently in progress.
26 Churg-Strauss syndrome in patients treated with omalizumab Omalizumab treatment may unmask CSS in patients who have an underlying eosinophilic disorder due to withdrawal of corticosteroids in favor of omalizumab, or may delay corticosteroid treatment allowing for CSS to manifest. Wechsler ME, et al. Chest 2009;136; org/ content/136/2/507.full.html
27 Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice Although efficacious, current therapeutic IgE- specific antibodies do not appear to affect IgE production and therefore must be given frequently and chronically to maintain sufficient suppression of serum IgE. Recently, a strategy was developed to disrupt IgE production by generating MAbs that target a segment of membrane IgE on human IgE-switched B cells that is not present in serum IgE. This may provide a novel treatment for asthma and allergy Brightbill HD, et al. J Clin Invest 2010;120(6):
28 Mepolizumab (anti-il IL-5 5 ab) IL-5 5 is believed to be a key cytokine in eosinophil function at sites of allergic inflammation. Humanized monoclonal antibodies against IL-5 5 have been synthesized. One such antibody, mepolizumab,, is a high- affinity humanized, non complement complement-fixing monoclonal antibody (IgG1) specific for human IL-5. Flood-Page P, et al. Am J Respir Crit Care Med 2007;176:
29 Mepolizumab (cont d) Pilot studies of anti IL IL-5 5 therapy showed profound reduction in both circulating and sputum eosinophils. However, in contrast to the results of animal studies, there was no significant effect of IL-5 blockade on either AHR or the late asthmatic response after allergen challenge, or sustained effect on lung function. Leckie MJ, et al. Lancet 2000; 356: Kips JC, et al. Am J Respir Crit Care Med 2003;167: Flood-Page PT, et al. Am J Respir Crit Care Med 2003;167:
30 A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Mean values for blood eosinophils Flood-Page P, et al. Am J Respir Crit Care Med 2007;176:
31 A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma A higher proportion of patients in the placebo and mepolizumab 250- mg treatment groups had an exacerbation of any level of severity during the study, compared with the mepolizumab 750-mg treatment group. Flood-Page P, et al. Am J Respir Crit Care Med 2007;176:
32 The Demise of Anti IL IL-5 5 for Asthma, or Not! Anti IL IL-5 5 has proven to be useful in managing hyper-eosinophilic eosinophilic syndromes. The results of clinical trials in patients with asthma with airway eosinophilia and poor control,, which are underway, are eagerly awaited, because they have implications not only for the possible role of anti IL IL-5 5 as a therapy for asthma but also in clarifying the role of airway eosinophils in its patho-biology. O Byrne PM. Am J Respir Crit Care Med 2007;176:
33 RECENT DATA Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma Severe Exacerbations during the Course of the Study. Panel A shows the cumulative number of severe exacerbations that occurred in each study group over the course of 50 weeks. Panel B shows the distribution of the number of exacerbations among subjects in each group during Haldar the P, et treatment al. N Engl period. J Med 2009;360:
34 RECENT DATA Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia Proportion of Patients without an Asthma Exacerbation during the Study Nair P, et al. N Engl J Med 2009;360:
35 Eosinophils in Asthma Closing the Loop or Opening the Door? Over the years, eosinophils were identified as a prominent cell type in asthma, yet their role as either an effector or innocent bystander was not confirmed. Recent studies confirm that in a subgroup of patients with eosinophilic asthma, mepolizumab therapy had some clinical benefit. However, many patients with asthma do not have eosinophilia,, and even in patients with eosinophilic asthma, mepolizumab had no effect on other physiological and clinical factors. Wenzel SE. N Engl J Med 2009;360;
36 Anti Tumor Necrosis Factor-alpha alpha in Asthma Therapy Positive results in treating asthma patients were challenged by other researches. There is also concern about serious problems and adverse events related to that kind of treatment especially in children. However, research on anti-tnf TNF-alpha and asthma underlined a significant polymorphism in asthma phenotypes. Therapy with anti-tnf TNF-alpha should be limited to a small subgroup of patients with a specific phenotype manifested by an increased TNF axis. Gjurow D, et al. Recent Pat Inflamm Allergy Drug Discov 2009;3(2):143 ):143-8.
37 The Effects of a Monoclonal Antibody Directed against TNF-alpha in Asthma (Infliximab) Exacerbations of Asthma The authors concluded that infliximab caused a decrease in the number of exacerbations in symptomatic moderate asthma. Erin EM, et al. Am J Respir Crit Care Med 2006;174:
38 A randomized DBPC study of TNF-alpha blockade in severe persistent asthma (Golimumab) Change from baseline in pre-bronchodilator percent-predicted predicted FEV1. The authors concluded that treatment with golimumab did not demonstrate a favorable risk benefit profile. Wenzel SE, et al. Am J Respir Crit Care Med 2009;179:
39 Correspondence: Anti TNF TNF-alpha in Asthma The incidence of anti TNF TNF- induced tuberculosis can be as high as 224/100,000 treated patients. Manifestations are often extra-pulmonary, and in 24% of the cases there is disseminated disease with a significant risk of death. The risk-benefit should be carefully considered as the protective effect of such treatment is estimated not to be higher than 60%. Therefore, studies on the therapeutic value of anti-tnf in asthma should be focused on patients with severe debilitating disease. Krouwels FH. Am J Respir Crit Care Med 2007;175(3):288.
40 Correspondence: Study of infliximab treatment in asthma The occurrence of neutralizing antibodies against infliximab is a common event, and this may compromise drug efficacy. Large multicenter, placebo-controlled, controlled, randomized, controlled trials in patients with severe chronic asthma are required before setting any recommendations. Edwards CJ, Polosa R. Am J Respir Crit Care Med 2007;175(2):196.
41 Anti-TGF beta MAb Neutralization of TGF-b1 with specific antibody had no significant effect on airway inflammation and eosinophilia It also enhanced ovalbumin induced AHR It suppressed pulmonary fibrosis. Alcorn JF, et al. Am J Respir Crit Care Med 2007;176:
42 Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a RDBPC trial The use of daclizumab, an anti-cd25 antibody, was associated with some improvement in lung function and asthma control along with a reduction in blood eosinophils. Busse WW, et al. Am J Respir Crit Care Med 2008;178:
43 Other Potential MAbs in Asthma Therapy A mutated interleukin-4 4 (pitrakinra) that binds the IL-4R 4Rαand blocks the effects of both IL-4 4 and IL-13 has been developed. A small RDBPC phase II trial in mild-to to- moderate asthmatics showed that inhaled pitrakinra reduced the late phase decline in lung function in response to inhalational allergen challenge with no serious adverse events. Wenzel SE, et al. Lancet 2007;370:
44 Other potential MAbs in asthma therapy (cont d) A phase 1 study evaluating the pharmacokinetics, safety and tolerability of a human IL-13 antibody (CAT-354) in asthma revealed an acceptable safety profile. Singh D, et al. BMC Pulm Med 2010;10:3. Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody (DX-2300 ) revealed a potential in vitro and in vivo role in airway diseases. Sexton DJ, et al. Biochem J 2009;422(2):
45 Other potential MAbs in asthma therapy (cont d) TH-17 cells may contribute to the pathogenesis of TH2-mediated allergic diseases, increase neutrophil infiltration and mucus proteins, and is associated with a steroid-resistant resistant asthma phenotype. Targeting TH-17 cells may be of value in severe neutrophilic asthma. In animal studies, a neutralizing antibody against IL-25 abrogates AHR, reduces IL-5 and IL-13 production, reduces tissue eosinophil infiltration, and serum IgE. Long AA. MAbs 2009; 1(3):
46 Other potential MAbs in asthma therapy (cont d) In vivo treatment with an anti-cd147 MAb significantly reduced the accumulation of eosinophils and antigen-specific Th2 cytokine secretion in lung tissues, airway epithelial mucin production, and AHR to methacholine challenge. Gwinn WM, et al. J Immunol 2006;177(7): Complexes of IL-2 2 / anti-il IL-2 2 MAb,, in a murine asthma model, reduced the severity of allergen-induced inflammation in the lung by expanding Tregs. Wilson MS, et al. J Immunol 2008;181(10):
47 Other potential MAbs in asthma therapy (cont d) T cell, immunoglobulin, mucin (TIM) genes are associated with several atopic diseases. A MAb against TIM-1 1 protein influenced activated T cells and blocked the development of disease in a humanized mouse model of allergic asthma suggesting that it may provide potent therapeutic benefit in asthma Sonar SS. J Clin Invest 2010;120(8):
48 Limitations of Use of MAbs in Asthma Expense Parenteral administration Adverse effects Host anti-drug responses limiting ongoing therapy Limitations in current concepts of molecular pathogenesis of disease
49 Take Home Message The cost-effectiveness and adverse events associated with the use of each monoclonal antibody should be considered. This could be achieved by carefully revising the existing clinical trials in light of solid evidence-based criteria. Pediatric data on cytokine-specific monoclonal antibody therapies are still needed.
50
51
52 Thank You Yehia El-Gamal
9/16/2014. Anti-Immunoglobulin E (IgE) Omalizumab (Xolair ) Dosing Guidance
Disclosure Statement of Financial Interest New Therapies for Asthma Including Omalizumab and Anti-Cytokine Therapies Marsha Dangler, PharmD, BCACP Clinical Pharmacy Specialist James H. Quillen VA Medical
More informationAsthma (With a little SCID to start) Disclosures Outline Starting with the Immune System The Innate Immune System The Adaptive Immune System
1 2 3 4 5 6 7 8 9 Asthma (With a little SCID to start) Lauren Smith, MD CHKD Pediatric Allergy/Immunology Disclosures None Will be discussing some medications that are not yet FDA approved Outline SCID
More informationImmunology and immunotherapy in allergic disease
Immunology and immunotherapy in allergic disease Jing Shen, MD Faculty Advisor: Matthew Ryan, MD The University of Texas Medical Branch Department of Otolaryngology Grand Rounds Presentation February 2005
More informationMontelukast Sodium. -A new class of seasonal allergic rhinitis therapy
Montelukast Sodium -A new class of seasonal allergic rhinitis therapy Symptoms of Seasonal Allergic Rhinitis Nasal itch Sneezing Rhinorrhoea Nasal stuffiness Pathogenesis of Allergic Rhinitis Mast cells,
More informationHypersensitivity. TYPE I Hypersensitivity Classic allergy. Allergens. Characteristics of allergens. Allergens. Mediated by IgE attached to Mast cells.
Gel and Coombs classification of hypersensitivities. Hypersensitivity Robert Beatty Type I Type II Type III Type IV MCB150 IgE Mediated IgG/IgM Mediated IgG Mediated T cell Classic Allergy rbc lysis Immune
More informationAntiYImmunoglobulin E Therapy
REVIEW ARTICLE AntiYImmunoglobulin E Therapy Manav Segal, Jeffrey R. Stokes and Thomas B. Casale Abstract: The importance of immunoglobulin E (IgE) in atopic disorders such as asthma, allergic rhinitis,
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationHow to use FENO-guided asthma control in routine clinical practice
How to use FENO-guided asthma control in routine clinical practice Asthma is a chronic inflammatory disease of the airways. This has implications for the diagnosis, management and potential prevention
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationunderstanding the professional guidelines
SEVERE ASTHMA understanding the professional guidelines This guide includes information on what the European Respiratory Society (ERS) and the American Thoracic Society (ATS) have said about severe asthma.
More informationBackground information
Background information Asthma Asthma is a complex disease affecting the lungs that can be managed but cannot be cured. 1 Asthma can be controlled well in most people most of the time, although some people
More informationOmalizumab for Asthma
clinical therapeutics Omalizumab for Asthma Robert C. Strunk, M.D., and Gordon R. Bloomberg, M.D. This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion
More informationBasics of Immunology
Basics of Immunology 2 Basics of Immunology What is the immune system? Biological mechanism for identifying and destroying pathogens within a larger organism. Pathogens: agents that cause disease Bacteria,
More informationSevere asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital
Severe asthma Definition, epidemiology and risk factors Mina Gaga Athens Chest Hospital Difficult asthma Defined as asthma, poorly controlled in terms of chronic symptoms, with episodic exacerbations,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationMicrobiology AN INTRODUCTION EIGHTH EDITION
TORTORA FUNKE CASE Microbiology AN INTRODUCTION EIGHTH EDITION Differentiate between innate and acquired immunity. Chapter 17 Specific Defenses of the Host: The Immune Response B.E Pruitt & Jane J. Stein
More informationBVIG/SBMI Meeting 2007. Bart N. Lambrecht, MD, PhD. Department of Respiratory Diseases University Hospital Gent, Belgium
Dendritic cells : from bench to bedside BVIG/SBMI Meeting 2007 Bart N. Lambrecht, MD, PhD Department of Respiratory Diseases University Hospital Gent, Belgium Outline Role of DCs in the immune system Role
More informationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
The new england journal of medicine original article Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma Hector G. Ortega, M.D., Sc.D., Mark C. Liu, M.D., Ian D. Pavord, D.M., Guy G. Brusselle,
More informationImmunosuppressive drugs
Immunosuppressive drugs RJM ten Berge Afd. Inw. Geneeskunde AMC contents overview targets mechanism of action Effects on immune capacity measured by responses to vaccination Immune response 1 calcineurin
More informationMULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist
MULTIPLE MYELOMA Dr Malkit S Riyat MBChB, FRCPath(UK) Consultant Haematologist Multiple myeloma is an incurable malignancy that arises from postgerminal centre, somatically hypermutated B cells.
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationObjectives. Asthma Management
Objectives Asthma Management BREATHE Conference Allergy and Asthma Specialists PC Christine Malloy MD March 22, 2013 Review the role of inflammation in asthma Discuss the components of the EPR-3 management
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationMaking the switch to a safer CAR-T cell therapy
Making the switch to a safer CAR-T cell therapy HaemaLogiX 2015 Technical Journal Club May 24 th 2016 Christina Müller - chimeric antigen receptor = CAR - CAR T cells are generated by lentiviral transduction
More informationAllergy Testing Test Request and Result Interpretation. Learning Objectives
Allergy Testing Test Request and Result Interpretation Dr. Kareena Schnabl, MSc, PhD, FCACB Clinical Biochemist, Genetic Laboratory Services University of Alberta Hospital Newborn Screening & Biochemical
More informationRheumatoid arthritis: an overview. Christine Pham MD
Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching
More informationEffects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
Early reports Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response Margaret J Leckie, Anneke ten Brinke, Jamey Khan, Zuzana
More informationCD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano, Jason Kato, David Pearson, Chengyi Xiong, Laura Newell, Yunpeng Ma, David R. Gandara,
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationIdiopathic Pulmonary Fibrosis (IPF) Research
Idiopathic Pulmonary Fibrosis (IPF): Why Early Referral is Critical Even if Your Patient is Not Eligible for a Clinical Trial Idiopathic Pulmonary Fibrosis (IPF) Research Management of IPF requires a confident
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationStanley J. Szefler, MD National Jewish Medical and Research Center
New Asthma Guidelines: Special Attention to Infant Wheezers Stanley J. Szefler, MD Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics, & Professor of Pediatrics and Pharmacology, University of Colorado
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationOKT3. ~ The first mouse monoclonal antibody. used in clinical practice in the field of transplantation ~
g944202 潘 怡 心 OKT3 ~ The first mouse monoclonal antibody used in clinical practice in the field of transplantation ~ As everybody knows, OKT3 is the first mouse monoclonal antibody produced for the treatment
More informationThe immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor
The immune system Basophil Neutrophil Bone marrow Eosinophil Myeloid progenitor Dendritic cell Pluripotent Stem cell Lymphoid progenitor Platelets Bone marrow Thymus NK cell T-cell B-cell Spleen Cancer
More informationPathophysiology of asthma
CHAPTER 5 Pathophysiology of asthma P.J. Barnes Correspondence: P.J. Barnes, Dept of Thoracic Medicine, National Heart and Lung Institute, Dovehouse St, London SW3 6LY, UK. Asthma is characterised by a
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationFastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections
More informationCompare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma
Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,
More information1) Siderophores are bacterial proteins that compete with animal A) Antibodies. B) Red blood cells. C) Transferrin. D) White blood cells. E) Receptors.
Prof. Lester s BIOL 210 Practice Exam 4 (There is no answer key. Please do not email or ask me for answers.) Chapters 15, 16, 17, 19, HIV/AIDS, TB, Quorum Sensing 1) Siderophores are bacterial proteins
More informationClinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
More informationPrevention of Acute COPD exacerbations
December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal
More informationThe Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationAntibody Function & Structure
Antibody Function & Structure Specifically bind to antigens in both the recognition phase (cellular receptors) and during the effector phase (synthesis and secretion) of humoral immunity Serology: the
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationpåçííáëü=jéçáåáåéë=`çåëçêíáìã==
påçííáëü=jéçáåáåéë=`çåëçêíáìã== adalimumab 40mg pre-filled syringe for subcutaneous injection (Humira ) No. (218/05) Abbott New indication: treatment of active and progressive psoriatic arthritis in adults
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd
ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
More informationMonoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
Eur Respir J 3; : 799 3 DOI:.3/9393.3.73 Printed in UK all rights reserved Copyright #ERS Journals Ltd 3 European Respiratory Journal ISSN 93-93 Monoclonal anti-interleukin- treatment suppresses eosinophil
More informationSummary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)
EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationThe Annual Direct Care of Asthma
The Annual Direct Care of Asthma The annual direct health care cost of asthma in the United States is approximately $11.5 billion; indirect costs (e.g. lost productivity) add another $4.6 billion for a
More informationmeasured before the start of treatment, and body weight (kg). See the dose determination charts. (2.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XOLAIR safely and effectively. See full prescribing information for XOLAIR. XOLAIR (omalizumab) for
More informationJ.P. Morgan Cazenove Therapeutic Seminar
Jannan, MS J.P. Morgan Cazenove Therapeutic Seminar David Meeker - CEO, Genzyme June 25, 2012 Forward Looking Statements This presentation contains forward-looking statements as defined in the Private
More informationplacebo-controlledcontrolled double-blind, blind,
Clinical Potential of Minocycline for Depression with Psychotic Features Tsuyoshi Miyaoka Department of Psychiatry Shimane University School of Medicine Minocycline 1. Second-generation tetracycline which
More informationEFFECTS OF IRON ON THE IMMUNE SYSTEM
EFFECTS OF IRON ON THE IMMUNE SYSTEM Gert Mayer Department of Internal Medicine IV (Nephrology and Hypertension) Medical University Innsbruck Austria Conflicts of interest Research Support: Amgen, Roche,
More informationName of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT)
Name of Policy: Antigen Leukocyte Cellular Antibody Test (ALCAT) Policy #: 165 Latest Review Date: February 2015 Category: Laboratory Policy Grade: C Background/Definitions: As a general rule, benefits
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationMechanisms of Sublingual Immunotherapy Guy Scadding ab ;Stephen Durham a a
This article was downloaded by: [Milani, Massimo] On: 20 April 2010 Access details: Access Details: [subscription number 921439129] Publisher Informa Healthcare Informa Ltd Registered in England and Wales
More informationExploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am
Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start
More informationRELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010
RELAPSE MANAGEMENT Pauline Shaw MS Nurse Specialist 25 th June 2010 AIMS OF SESSION Relapsing/Remitting MS Definition of relapse/relapse rate Relapse Management NICE Guidelines Regional Clinical Guidelines
More informationGuideline on the clinical investigation of medicinal products for the treatment of asthma
22 October 2015 CHMP/EWP/2922/01 Rev.1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of Draft Agreed by Respiratory
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationAsthma diagnosis and treatment: Filling in the information gaps
Asthma: Current status and future directions Asthma diagnosis and treatment: Filling in the information gaps William W. Busse, MD Madison, Wis Current approaches to the diagnosis and management of asthma
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationWilliam E. Berger, M.D., M.B.A. Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine
Allergic Reactions & Access to Emergency Response William E. Berger, M.D., M.B.A. Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine Mechanistic
More informationIn vitro co-culture model of the inflamed intestinal mucosa
In vitro co-culture model of the inflamed intestinal mucosa Berlin, December 13, 2011 Eva-Maria Collnot, e.collnot@mx.uni-saarland.de Helmholtz Institute for Pharmaceutical Research Saarland Departement
More informationTransgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO
Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO Statistically significant difference in progression-free survival continues to be seen in non-squamous
More informationEpidemiological Studies on Environmental Stressors from Tobacco to Pesticides
Epidemiological Studies on Environmental Stressors from Tobacco to Pesticides W. Susan Cheng, PhD, MPH Rebecca Carlstrom, MPH Sukaina Hussain, MPH Healthy Lawn Symposium Oct 31, 2014 Two Presentations
More informationRecombinant allergens provide new opportunities. The diagnostic tools of tomorrow are already here
Recombinant allergens provide new opportunities The diagnostic tools of tomorrow are already here Recombinant allergens provide new opportunities The diagnostic tools of tomorrow are already here Today
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization
More informationThe Immune System: A Tutorial
The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationCorporate Medical Policy Allergy Immunotherapy (Desensitization)
Corporate Medical Policy Allergy Immunotherapy (Desensitization) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allergy_immunotherapy 7/1979 11/2014 11/2015 10/2015 Description
More informationTechnological platforms
Advitech Advitech is a life sciences & technology company Its mission is to discover and commercialize proprietary and evidence-based natural health products Focus on milk, whey and bovine colostrum R&D,
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationPersonalised Medicine in MS
Personalised Medicine in MS Supportive Evidence from Therapeutic Trials Ludwig Kappos Neurology and Department of Biomedicine University Hospital CH-4031 Basel LKappos@uhbs.ch Established partially effective
More informationCurrent Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
More informationAnti-IgE therapy with omalizumab in asthma and allergic rhinitis
Acta Pharm. 55 (2005) 123 138 Review article Anti-IgE therapy with omalizumab in asthma and allergic rhinitis SLAVICA DODIG 1* DARKO RICHTER 1 IVANA ^EPELAK 2 BOJAN BENKO 3 1 Special Hospital for Respiratory
More informationCompany Presentation June 2011 Biotest AG 0
Company Presentation June 2011 0 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PDP IBT Inj - Vivitrol Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Opiate Antagonist Client: 2007 PDP IBT Inj Approval Date: 2/20/2007
More informationPulmonary interstitium. Interstitial Lung Disease. Interstitial lung disease. Interstitial lung disease. Causes.
Pulmonary interstitium Interstitial Lung Disease Alveolar lining cells (types 1 and 2) Thin elastin-rich connective component containing capillary blood vessels Interstitial lung disease Increase in interstitial
More informationActivation and effector functions of HMI
Activation and effector functions of HMI Hathairat Thananchai, DPhil Department of Microbiology Faculty of Medicine Chiang Mai University 25 August 2015 ว ตถ ประสงค หล งจากช วโมงบรรยายน แล วน กศ กษาสามารถ
More informationClinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
More informationSide effect of drugs, such as amphetamines, tranquilizers, bulk-type laxatives containing psyllium and certain antibiotics
Eosinophils Eosinophils are a type of white blood cell. A normal eosinophil count is less than 350 cells per microliter of blood. The exact role of eosinophils in your body is unclear, but eosinophils
More informationA disease and antibody biology approach to antibody drug discovery
A disease and antibody biology approach to antibody drug discovery Björn Frendéus, PhD VP, Preclinical research Presenter: Björn Frendéus Date: 2011-11-08 1 Antibodies have revolutionized Cancer Treatment!
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationUnderstanding How Existing and Emerging MS Therapies Work
Understanding How Existing and Emerging MS Therapies Work This is a promising and hopeful time in the field of multiple sclerosis (MS). Many new and different therapies are nearing the final stages of
More informationCircular Instructions related to occupational lung diseases
Circular Instructions related to occupational lung diseases Compensation Fund Dr Monge Lekalakala OCCUPATIONAL DISEASES According to Section 65(1) of the COID ACT: a) An Occupational disease disease arising
More informationGlossary of Terms. Section Glossary. of Terms
Glossary of Terms Section Glossary of Terms GLOSSARY Acute: Symptoms which can occur suddenly with a short and severe course. Adrenaclick /Generic Adrenaclick : a single use epinephrine auto-injector that
More information